California startup Apama Medical raised $3.2 million in a Series A-1 financing round in support of a catheter-based technology that the company says is "vastly superior" in treatment of atrial fibrillation.
The company offered few details about the device in the press release or on its minimal website, but noted that it hopes to enter an atrial fibrillation mapping and ablation market that it expects to reach $2 billion by 2017.
The funding round was a coast-to-coast effort, with financing led by Boston-based Broadview Ventures.
Apama Medical grew out of Shifamed LLC, a technology incubator focused on bring medical technologies "from concept to commercial release," according to a company statement.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.